Responsible, Safe, and Effective Use of Biologics in the Management of Low Back Pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines.
Navani A., Manchikanti L., Albers SL., Latchaw RE., Sanapati J., Kaye AD.
Systematic Review on Back Pain, published in Pain Physician (2019) — summary generated from the PubMed abstract.
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Systematic Review
- Journal
- Pain Physician (2019)
- Country
- United States
- Reported sample size
- —
- PMID
- 30717500
Abstract (original English)
Regenerative medicine is a medical subspecialty that seeks to recruit and enhance the body's own inherent healing armamentarium in the treatment of patient pathology. This therapy's intention is to assist in the repair, and to potentially replace or restore damaged tissue through the use of autologous or allogenic biologics. This field is rising like a Phoenix from the ashes of underperforming conventional therapy midst the hopes and high expectations of patients and medical personnel alike. But, because this is a relatively new area of medicine that has yet to substantiate its outcomes, care must be taken in its public presentation and promises as well as in its use. To provide guidance for the responsible, safe, and effective use of biologic therapy in the lumbar spine. To present a template on which to build standardized therapies using biologics. To ground potential administrators of biologics in the knowledge of the current outcome statistics and to stimulate those interested in providing biologic therapy to participate in high quality research that will ultimately promote and further advance this area of medicine. The methodology used has included the development of objectives and key questions. A panel of experts from various medical specialties and subspecialties as well as differing regions collaborated in the formation of these guidelines and submitted (if any) their
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.
How we grade evidenceRelated research
- Level ASystematic Review
Comprehensive Evidence-Based Guidelines for Regenerative Therapies in the Management of Chronic Low Back Pain: 2025 Update from the American Society Of Interventional Pain Physicians (ASIPP).
Systematic Review on Back Pain, Scar, published in Pain Physician (2025) — summary generated from the PubMed abstract.
- 2025
Pain Physician - Level ASystematic Review
Mesenchymal Stromal Cells for the Treatment of Discogenic Low Back Pain: A Systematic Review of Clinical Studies.
Systematic Review with a reported sample of 736 on Back Pain, Disc Degeneration, published in Neurospine (2025) — summary generated from the PubMed abstract.
- 2025
- n = 736
Neurospine - Level ASystematic Review
Stem cells and discogenic back pain.
Systematic Review with a reported sample of 303 on Back Pain, Disc Degeneration, published in Br Med Bull (2023) — summary generated from the PubMed abstract.
- 2023
- n = 303
Br Med Bull - Level ASystematic Review
Potential Role for Stem Cell Regenerative Therapy as a Treatment for Degenerative Disc Disease and Low Back Pain: A Systematic Review.
Systematic Review on Back Pain, Disc Degeneration, published in Int J Mol Sci (2023) — summary generated from the PubMed abstract.
- 2023
Int J Mol Sci - Level ASystematic Review
A systematic review of the safety and efficacy of mesenchymal stem cells for disc degeneration: insights and future directions for regenerative therapeutics.
Systematic Review on Back Pain, Disc Degeneration, published in Stem Cells Dev (2014) — summary generated from the PubMed abstract.
- 2014
Stem Cells Dev - Level BClinical Trial
Safety and Feasibility of Intradiscal Administration of Matrilin-3-Primed Adipose-Derived Mesenchymal Stromal Cell Spheroids for Chronic Discogenic Low Back Pain: Phase 1 Clinical Trial.
Clinical Trial on Back Pain, Disc Degeneration, published in Int J Mol Sci (2023) — summary generated from the PubMed abstract.
- 2023
Int J Mol Sci